Trips Agreement Vaccine

In fact, the new technology, which is at the heart of the Moderna vaccine, was partly developed by the National Institutes of Health with U.S. federal funds. Moderna received a total of approximately $2.5 billion in taxpayers` money to support research and pre-order vaccines; By his own admission, the contribution he received for research covered 100 per cent of these costs. The news of the possibility of a COVID-19 vaccine is hopeful, but every time it is ready, millions of people around the world will have to wait years to access it. This delay is partly due to global IP rules that create barriers to knowledge exchange, which could otherwise lead to wider and faster access. For its part, Pfizer received a $455 million grant from the German government for the development of its vaccine, and then, according to our count, nearly $6 billion in purchase commitments from the United States and the European Union. It is clear that a temporary waiver of the TRIPS agreement will not be a panacea for countries seeking access to life-saving vaccines. Anticipation is long and without the collaboration of leading pharmaceutical innovators, it is unlikely that competing generic manufacturers will be put into service immediately, even if they have access to patented drugs and technologies. Countries saw a common goal of ensuring access to safe, effective and affordable vaccines and medicines for all, but failed to reach consensus on a waiver, the official said. Discussions are expected to continue in 2021 beyond the end of the year. „There are capabilities that could be put in place in the long term,“ he said, especially with the vaccine calling for „new technologies, platform technologies that will be very important for other drugs and vaccines. There are mechanisms for low-income countries to end patents and ensure their citizens have affordable access to new vaccines and treatments, but they must act now.

Access to COVID-19 Accelerator Tools and its COVAX vaccine distribution device, which is seen as evidence of international solidarity in the face of the pandemic, are struggling this year with a deficit of $4.3 billion and the need to raise $23.9 billion in 2021. And COVAX has always been only an obligation to provide 20% of the necessary vaccines, which is not the estimated 60% coverage to achieve herd immunity.